Han Kiwon, Commissioner, Invest Korea
The head of the government agency charged with attracting and promoting FDI in Korea discusses how the country has ideally positioned itself between China and western markets through a series…
Invest Korea (IK), Korea’s national investment promotion agency, was established within the Korea Trade-Investment Promotion Agency (KOTRA) with the sole purpose of supporting the entry and successful establishment of foreign business into Korea. With assistance extending to comprehensive post-establishment services, IK enables foreign corporations to maximize the benefits of the Korean investment environment to ensure their rapid settlement in Korea. The agency is committed to providing unmatched, comprehensive one-stop service that allows foreign investors to join many of the world’s most successful corporations who have selected Korea as an investment destination and been rewarded by high returns on the investment.
Contact Details
13, Heolleung-ro Seocho-gu,
Seoul
Republic of Korea (137-749)
Tel. 82-1600-7119
E-mail ikonline@kotra.or.kr
The head of the government agency charged with attracting and promoting FDI in Korea discusses how the country has ideally positioned itself between China and western markets through a series…
Could you please give a brief presentation of Invest Korea to our readers? Invest Korea is the national investment promotion agency, responsible for attracting FDI into Korea. We have existed…
A roundup of some of the biggest stories from South Korean healthcare and pharma, including the government’s continuing standoff with doctors over medical reform plans; Merck’s plans for a new…
Despite its ageing population and growing need for healthcare, South Korea had just 2.6 doctors per 1,000 inhabitants in 2022, one of the lowest numbers among developed nations. To deal…
The latest pharma and healthcare news from APAC, including Celltrion’s plans to sell its Takeda portfolio to CBC; reforms to the South Korean national insurance system that may lead to…
Global medtech giant Medtronic is hoping that its latest acquisition – EOFlow, a South Korean wearable insulin patch maker – will enhance its competitiveness in the global diabetes market. …
A roundup of some of the most important recent stories from the burgeoning South Korean pharma and biotech industry, including a government plan to expand collaboration with the global innovation…
As big pharma continues to sharpen its focus on R&D by outsourcing other elements of the supply chain, including manufacturing, CDMOs have thrived. Samsung Biologics, one of the world’s top…
After launching the first Korean COVID-19 vaccine, SKYCovione, SK Bioscience is preparing for its next big milestone, a US subsidiary, with the appointment of two new executives who are already…
SK Bioscience’s announcement that the first batch of its domestically developed COVID vaccine has been shipped may mark a significant milestone in South Korea’s journey towards greater vaccine self-sufficiency. …
ExoCoBio’s CEO, Byong Seung Cho, went from biotech venture capital to setting up ExoCoBio, a company whose core technology is based on adipose stem-cell derived exosomes for regenerative medicine and…
South Korea has carved a place for itself as a dominant player in the global pharma and med-tech manufacturing industry with national companies Samsung Biologics and Celltrion leading the way.…
After a dynamic two years as CEO of Samsung Biologics, John Rim highlights some of the fundamentals behind the company’s rapid growth as a CDMO, including the creation of huge…
Stephen Yoo highlights the pioneering work that STCube Pharmaceuticals – a US subsidiary of Korean firm STCube – is undertaking in the immuno-oncology field, its three technology platforms, partnership approach,…
See our Cookie Privacy Policy Here
